A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Everolimus (Primary)
- Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours
- Focus Registrational; Therapeutic Use
- Acronyms RADIANT-4
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 15 Apr 2021 Results of post hoc pooled analysis from RADIANT-3 and RADIANT-4, published in the Cancer.
- 13 Sep 2020 This trial is completed in Austria (Global End Date: 07 Aug 2020), according to European Clinical Trials Database record.
- 01 Sep 2020 This trial has been completed in Poland.